安体舒通联合氢氯噻嗪对2型糖尿病肾病蛋白尿的影响

发布时间：2018-01-18 15:23

本文关键词：安体舒通联合氢氯噻嗪对2型糖尿病肾病蛋白尿的影响　出处：《中国现代医学杂志》2015年05期 　论文类型：期刊论文

【摘要】：目的探讨安体舒通联合氢氯噻嗪治疗2型糖尿病肾病的安全性及其对蛋白尿的影响。方法将2型糖尿病肾病患者随机分为3组,治疗组(安体舒通+氢氯噻嗪)、安体舒通组、氢氯噻嗪组,每组20例。治疗组给予安体舒通40 mg/d+氢氯噻嗪25 mg/d口服;安体舒通组予以安体舒通40 mg/d口服;氢氯噻嗪组予25 mg/d口服,持续3个月,定期测量患者血压、生化指标及24 h尿蛋白定量。结果与氢氯噻嗪组比较,治疗组及安体舒通组24 h尿蛋白显著下降(P0.001);安体舒通组血钾显著上升(P=0.002),治疗组及氢氯噻嗪组血钾无显著变化。结论安体舒通联合氢氯噻嗪可以显著降低2型糖尿病患者的蛋白尿而不升高血钾。
[Abstract]:Objective to investigate the safety and effect on proteinuria of patients with type 2 diabetic nephropathy treated with acetonolactone and hydrochlorothiazide. Methods patients with type 2 diabetic nephropathy were randomly divided into 3 groups. The treatment group (20 cases in each group) were treated with acetonolactone hydrochlorothiazide, androsolactone group, hydrochlorothiazide group (n = 20). The treatment group was administered orally for 40 mg/d with hydrochlorothiazide for 25 mg/d. The group of acetonolactone was administered orally for 40 mg/d; Hydrochlorothiazide group was administered orally for 25 mg/d for 3 months. The blood pressure, biochemical indexes and 24 h urine protein were measured regularly. Results the results were compared with those of hydrochlorothiazide group. In the treatment group and in the acetonolactone group, the urinary protein decreased significantly at 24 h (P 0.001). The serum potassium in the group of acetonolactone increased significantly (P0. 002). Conclusion the combination of acetonolactone and hydrochlorothiazide can significantly reduce the proteinuria of type 2 diabetes without increasing serum potassium.
【作者单位】：南华大学附属第一医院肾内科;
【分类号】：R587.2;R692.9
【正文快照】： 肾小球肥大,微量白蛋白尿,明显蛋白尿,进行性肾小球滤过率(glomerular filtration rate,GFR)下降是糖尿病肾病的病程特征,而蛋白尿是心肾疾病进展的重要危险因素,减少蛋白尿可能延缓GFR下降[1],血管紧张素转化酶抑制剂(angiotensin convert-ing enzyme inhibitors,ACEI)和血管

【参考文献】